The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA)... Dec 03
The company is encouraged by the patient's strong response to Silmitasertib and will make every effort to provide the drug to critically ill COVID-... Sep 12
-Advertisements-